SEQUENCE SPECIFIC SYNTHETIC MRNA CLEAVING AGENTS

NIH RePORTER · NIH · R41 · $100,000 · view on reporter.nih.gov ↗

Abstract

The objective of this research is to improve the efficacy of action of antisense oligonucleotides by equipping them with RNA specific cleaving agents. Recently, a series of lanthanide complexes have been designed, synthesized, and characterized by Janet Morrow and co-workers (SUNY) which catalyze the hydrolysis of the phosphodiester bond of RNA, and are inert to metal ion- dissociation in solution. Two of these metal complexes, La(S-ThP)3+ and Eu(THED)3+, will be covalently attached to an antisense oligonucleotide that targets the mutant Ha-ras transcript. The conjugates will be tested for activity in solution and cell culture assays. Improvement in activity resulting from the incorporation of this new technology into the existing repertoire of antisense technologies will encourage further development and potential commercialization of this new class of compounds for the treatment of infectious and non-infectious diseases.

Key facts

NIH application ID
2190321
Project number
1R41GM051646-01
Recipient
ISIS PHARMACEUTICALS, INC.
Principal Investigator
BRENDA F BAKER
Activity code
R41
Funding institute
NIH
Fiscal year
1994
Award amount
$100,000
Award type
1
Project period
1994-07-01 → 1995-06-30